Vincerx Pharma (VINC) Projected to Post Quarterly Earnings on Friday

Vincerx Pharma (NASDAQ:VINC) is anticipated to post its quarterly earnings results before the market opens on Friday, April 4th. Analysts expect Vincerx Pharma to post earnings of ($2.60) per share for the quarter.

Vincerx Pharma Stock Performance

VINC opened at $0.57 on Friday. The firm’s fifty day moving average is $1.28 and its two-hundred day moving average is $5.33. Vincerx Pharma has a twelve month low of $0.49 and a twelve month high of $136.80. The firm has a market cap of $1.27 million, a PE ratio of -0.03 and a beta of 1.43.

Vincerx Pharma Company Profile

Vincerx Pharma, Inc, a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors.